Urologic Oncology-seminars and Original Investigations最新文献

{"title":"Impact of obesity on prostatectomy outcomes: Insights from a large prospectively maintained cohort.","authors":"Ekamjit S Deol, Kelly S Lehner, Anthony E Fadel, Laureano J Rangel, Abhinav Khanna, Matthew K Tollefson, Paras H Shah, Igor Frank, Stephen A Boorjian, R Jeffrey Karnes, Vidit Sharma","doi":"10.1016/j.urolonc.2025.01.014","DOIUrl":"https://doi.org/10.1016/j.urolonc.2025.01.014","url":null,"abstract":"<p><strong>Background: </strong>In this study we aimed to explore the impact of BMI on perioperative complications, functional outcomes, and oncologic outcomes and longitudinal outcomes.</p><p><strong>Methods: </strong>We queried our prospectively maintained radical prostatectomy (RP) registry from 1986 to 2018 for patients with cM0 prostate adenocarcinoma without prior BPH surgery or radiation therapy. Preoperative BMI was associated with the following outcomes of interest: 30-day complications, 1-year functional outcomes, and oncologic outcomes. Logistic regression analyses were used for complications and surgical outcomes and competing risk Cox proportional hazard models were used for oncologic outcomes.</p><p><strong>Results: </strong>In a cohort of 21,604 patients, 28.9% and 1.0% had BMI > 30 (N = 6,252) and BMI > 40 (N = 222), respectively. Obese patients were more likely to have positive surgical margins (29.4% vs. 25.0%, P < 0.001) and early complications (15.0% vs. 11.1%, P < 0.001) and these were confirmed on multivariable analysis: OR 1.04 (P < 0.001) and OR 1.04 (P < 0.001), respectively. RP on obese patients also had increased operative times and blood loss. Increasing BMI was associated with lower odds for recovering potency (OR 0.95, P < 0.001) but was not associated with lower rates of postoperative continence (OR 1.005, P = 0.403). On multivariable competing risk analysis, patients with BMI > 30 had higher odds of nonprostate cancer mortality but no difference in biochemical failure, metastasis or cancer-specific survival.</p><p><strong>Conclusions: </strong>RP in obese patients can be technically challenging but delivers similar oncologic outcomes to nonobese patients. This information can be useful for patient counseling to support the use of radical prostatectomy in appropriately selected obese patients.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143789195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pattern and risk factors of local recurrence and intravesical recurrence after segmental ureterectomy for upper tract urothelial carcinoma.","authors":"Bao Guan, Silu Chen, Zihao Tao, Yueyuan Jiang, Zhenyu Li, Chunru Xu, Gengyan Xiong, Qi Tang, Yang Liu, Hongzhen Li, Xianshu Gao, Liqun Zhou, Xuesong Li, Xiaoying Li","doi":"10.1016/j.urolonc.2025.03.008","DOIUrl":"https://doi.org/10.1016/j.urolonc.2025.03.008","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the pattern and risk factors of local recurrence and intravesical recurrence of ureteral upper tract urothelial carcinoma (UTUC) following segmental ureterectomy (SU).</p><p><strong>Methods: </strong>From February 2012 to August 2021, a retrospective analysis was conducted on patients following SU. Univariate and multivariate Cox regression analysis were used to evaluate the risk factors. Kaplan-Meier curves were employed to illustrate survival outcomes.</p><p><strong>Results: </strong>Among 88 patients, 50 (57%) were male, with a median age of 71 (IQR: 62-77) years. The procedures of ureteral reconstruction included ureteral reimplantation in 77 (88%) cases, ureteroureteral anastomosis in 9 (10 %) cases, Boari flap ureteroplasty with psoas hitch in 1 (1%) case, and cutaneous ureterostomy in 1 (1%) case. The median follow-up time was 44.5 months. The 3-year rate of local recurrence, lymph node metastasis, ipsilateral upper urinary tract recurrence and intravesical recurrence was 31.6%, 19.0%, 22.2% and 35.7%, respectively. G3 (HR = 3.355, 95% CI 1.375-8.184, P = 0.008), and lymphatic vascular infiltration (HR = 3.127, 95% CI 1.043-9.373, P = 0.042) were independent risk factors for local recurrence. G3 (HR = 3.782, 95% CI 1.036-13.812, P = 0.044) was an independent risk factor for lymph node metastasis. Sarcomatoid differentiation (HR = 3.943, 95% CI 1.087-14.308, P = 0.037) was an independent risk factor for ipsilateral upper urinary tract recurrence. Previous or concurrent bladder cancer (HR = 3.280, 95% CI 1.667-6.453, P = 0.001) and sarcomatoid differentiation (HR = 4.442, 95% CI 1.317-14.989, P = 0.016) were independent risk factor for intravesical recurrence. The most common regions for bladder recurrence were posterior wall (21%), same lateral wall (16%) and trigon (16%).</p><p><strong>Conclusion: </strong>SU is a feasible treatment for selected UTUC patients, yet it is associated with a considerable risk of local and intravesical recurrence. Careful monitoring and active adjuvant therapy are essential to minimize the recurrence rate for patients with risk factors.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143789197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prophylactic heparin does not increase clinically significant bleeding following transurethral resection of a bladder tumor.","authors":"Eric Regele, Katherine Beran, Kunal Hanchate, Alex Hochwald, Michael A Edwards, Andrew J Zganjar, Timothy D Lyon","doi":"10.1016/j.urolonc.2025.03.017","DOIUrl":"https://doi.org/10.1016/j.urolonc.2025.03.017","url":null,"abstract":"<p><strong>Introduction: </strong>Transurethral resection of bladder tumor (TURBT) is a high bleeding risk procedure due to resection over a mucosal surface and is often performed in patients with risk factors for venous thromboembolism (VTE). Limited data exist to inform the risks and benefits of prophylactic heparin before TURBT. We sought to assess whether preoperative heparin was associated with clinically significant bleeding after TURBT.</p><p><strong>Methods: </strong>We retrospectively identified 583 consecutive patients who underwent TURBT between Jan 1, 2021 and April 30, 2023. In April 2022 we began routinely administering 5,000 units of subcutaneous heparin at anesthesia induction during TURBT. The primary outcome was clinically significant bleeding within 30 days of TURBT, defined as reoperation for clot evacuation/fulguration, clot retention, blood transfusion, and/or continuous bladder irrigation.</p><p><strong>Results: </strong>Among 583 patients, 220 (38%) received preoperative heparin and 363 (62%) did not. Twenty-five patients experienced a bleeding event, including 6 (2.7%) in the heparin group and 19 (5.2%) in the no heparin group (P = 0.25). After adjusting for sex and tumor size, heparin was not significantly associated with clinically significant bleeding (adjOR 0.51, 95% CI, 0.18-1.2, P = 0.16). Three patients (0.5%) experienced a 30-day VTE, including 1 (0.5%) in the heparin group and 2 (0.6%) in the group without heparin (P = 0.9).</p><p><strong>Conclusion: </strong>We did not observe a statistically significant difference in the rate of clinically significant bleeding within 30 days of TURBT between patients treated with and without preoperative heparin, suggesting that preoperative heparin can be considered among patients at high risk of postoperative VTE.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143789253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increase in workload among genitourinary oncologists drives burnout: Insights from the BUCARE survey.","authors":"Alisher Kahharov, Ilya Tsimafeyeu, Dilyara Kaidarova, Djamilya Polatova, Fuad Guliyev, Bakytzhan Ongarbayev, Ramil Abdrakhmanov, Timur Mitin","doi":"10.1016/j.urolonc.2025.03.019","DOIUrl":"https://doi.org/10.1016/j.urolonc.2025.03.019","url":null,"abstract":"<p><strong>Background: </strong>Burnout is a significant issue among GU oncologists, driven by increasing workloads and the emotional demands of patient care. This study aims to identify the prevalence, risk factors, and potential interventions to address burnout in this population.</p><p><strong>Methods: </strong>A comprehensive survey, including a visual mood assessment, was conducted among 674 GU oncologists. The survey assessed work conditions, mood, and burnout indicators, alongside demographic and professional characteristics.</p><p><strong>Results: </strong>Among the respondents, 72% (482 out of 674) displaying symptoms of burnout, characterized by high emotional exhaustion and/or depersonalization. Key risk factors included long working hours (more than 8 hours per day for 54% of respondents), high patient volumes (48% managing over 15 patients daily), and night shifts (16%). Despite signs of burnout in 72% of participants, a visual mood assessment showed that 72% reported being in a good or excellent mood. Additionally, 92% of respondents expressed passion for their work, and 84% showed a strong desire for professional development.</p><p><strong>Conclusions: </strong>Burnout is prevalent among GU oncologists, despite their dedication to their profession. Strategic interventions, such as expanding the workforce and reducing daily patient volumes, are essential to mitigate burnout and improve well-being.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143789196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Urinary leak after partial nephrectomy: Insights from a cohort with hereditary, multifocal, and reoperative cases.","authors":"Ruben Blachman-Braun, Milan Patel, Lauren Loebach, Braden Millan, Jaskirat Saini, Sandeep Gurram, W Marston Linehan, Mark W Ball","doi":"10.1016/j.urolonc.2025.03.013","DOIUrl":"https://doi.org/10.1016/j.urolonc.2025.03.013","url":null,"abstract":"<p><strong>Purpose: </strong>To identify risk factors, surgical considerations, and management strategies associated with urinary leak (UL) following partial nephrectomy (PN) in a cohort that includes a significant number of patients with hereditary renal cancer syndromes, multiple tumors, and a history of prior PNs.</p><p><strong>Material and methods: </strong>A retrospective chart review was conducted selecting patients who underwent PN at our institution from January 2006 to December 2023 was performed. Clinical, demographic, surgical characteristics, and management strategies were recorded and analyzed.</p><p><strong>Results: </strong>A total of 1,173 PNs were analyzed, of those 89(7.6%) had a UL. Patients had a median age at surgery of 50[38-59] years, 3[1-6] tumors removed per procedure with a total of 5,947 tumors were removed, 61.6% PN via the robotic approach, and the most common diagnosis was von Hippel-Lindau disease (47.4%). The frequency of UL was 5.1% for first-time PN, 10.4% for second, and 19.6% for third. An increased risk of UL was observed with higher EBL (OR = 1.016; P = 0.006) and decrease with robotic approach (OR = 0.376; P < 0.001). Overall, 44.9% of UL cases were successfully managed with conservative management (postop drain and Foley), while 98.9% were successfully managed with conservative management, ureteral stent placement, percutaneous drain, or nephrostomy tube.</p><p><strong>Conclusion: </strong>UL is directly associated with the complexity of the surgery. The advantages of robotic-assisted surgery in reducing UL risk indicate potential avenues for improved outcomes. Future efforts should explore the role of intraoperative and postoperative strategies to minimize this complication. Conservative management and drain or catheter placement resolve most of the ULs.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two-year resource utilization of open vs. robot-assisted radical cystectomy: Results from optum's de-identified clinformatics® data mart database.","authors":"Shaun Trecarten, Caroline Schaefer, Ahmed Elshabrawy, Ahmad Abdelaziz, Emad Dalla, Furkan Dursun, Trudy Krause, Michael Liss, Dharam Kaushik, Robert Svatek, Ahmed M Mansour","doi":"10.1016/j.urolonc.2025.03.002","DOIUrl":"https://doi.org/10.1016/j.urolonc.2025.03.002","url":null,"abstract":"<p><strong>Purpose: </strong>Despite increasing adoption of robotic radical cystectomy (RRC), its cost-effectiveness remains in question. Therefore, we aimed to compare 2-year resource utilization (RU) between RRC and open radical cystectomy (ORC).</p><p><strong>Methods: </strong>Queried from Optum's de-identified Clinformatics® Data Mart Database, patients diagnosed with bladder cancer who underwent radical cystectomy were identified between 2014 and 2017. Patients with ≥2 years of continuous enrollment were stratified by open and robotic approach. RU was evaluated from incident hospitalization costs and total standardized costs over 2 years for each subsequent inpatient/outpatient visit. Multivariate generalized linear regression (MGLR) was used to determine the impact of surgical approach on subsequent RU.</p><p><strong>Results: </strong>About 2,373 patients were identified. Of patients with continuous enrollment for ≥2 years (N = 1353), 798 (59%) underwent RRC and 555 (41%) underwent ORC. RRC was associated with lower RU than ORC, ($65,188.02 vs. $80,375.90, P < 0.0001) and lower inpatient costs for incident hospitalization ($29,142 vs. $42,329, P < 0.001). RRC, versus ORC, demonstrated shorter median length of hospital stay (5 vs. 7 days, P < 0.0001), and was associated with lower rates of acute kidney failure (3% vs. 5%, P = 0.007), ileus (2% vs. 5%, P = 0.005) and blood transfusions (≤ 2% vs. 6%, P < 0.001). MGLR demonstrated that robotic approach independently reduced total cost (β 0.84, CI 0.77-0.93, P < 0.001).</p><p><strong>Conclusions: </strong>RRC is associated with reduced 2-year RU and incident hospitalization costs compared to ORC. Robotic technique was independently associated with lower total costs. While granular cost metric details are limited, the reduced RU with RRC represents a novel assessment of reduced postoperative morbidity.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Organ preservation and oncological efficacy of peniscopically controlled CO₂ laser excision of penile squamous cell carcinoma: Early and late results in a high-volume center.","authors":"Sebastiano Nazzani, Vito Lorusso, Mario Catanzaro, Tullio Torelli, Carlo Silvani, Alberto Macchi, Davide Biasoni, Ruggero Darisi, Claudia Colbacchini, Silvia Stagni, Antonio Tesone, Melanie Claps, Patrizia Giannatempo, Matteo Zimatore, Laura Cattaneo, Emanuele Montanari, Nicola Nicolai","doi":"10.1016/j.urolonc.2025.02.024","DOIUrl":"https://doi.org/10.1016/j.urolonc.2025.02.024","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate safety and early and long-term efficacy of CO₂ laser conservative treatments for nonulcerative squamous cell carcinoma (SCC) of the penis.</p><p><strong>Material and methods: </strong>Within our institutional database (2002-2022, included), we identified 122 consecutive cT1-2 cN0 cM0 patients with penile SCC who underwent conservative CO₂ laser treatments. Histologically confirmed local relapses were recorded. Local relapses were classified as early recurrences when occurring <2 years and as late new tumor recurrences when occurring >2 years after first laser treatment. Predictors of disease relapse were analyzed with univariable and multivariable Cox regression models (MCRMs).</p><p><strong>Results: </strong>Median follow-up was 36 months [Interquartile range (IQR) 21-73 months]. Median age was 62 years (IQR: 51-69 years). Median largest lesion size was 10 mm (IQR 5-15 mm). 62 patients had penile intraepithelial neoplasia (PeIN) (51.6%), 30 had pT1 m (24.6%), 28 had pT1 (23%) and 1 had pT2 (0.8%), 2 patients were classified as pTx. In case of invasive lesions, tumor Grade was G1 in 37 (60.7%), G2 in 20 (32.8%), G3 in 4 (6.5%). Early and late recurrences occurred in 28 (22%) and in 21 patients (18%), respectively. Proportion of penis preservation was 93.4% and 92.6% at 2 and 5 years. pT1 stage [Hazard Ratio (HR) 13, Confidence Interval (CI) 1.4-73, p-value 0.02] and flat lesions (HR 7.9, CI 1.06-59, 0.04) achieved independent predictor status for late recurrences. No cancer related deaths were recorded after a median follow-up of 36 months.</p><p><strong>Conclusions: </strong>As far as we know, this is the largest cohort of patients with penile cT1-T2 SCC who underwent conservative CO₂ laser treatment. The vast majority (92%) of these patients preserved their organ at 5 years. Some factors can be of use in preventing or anticipating late recurrences.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143765223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential response of low- and high-grade intermediate-risk non-muscle-invasive bladder cancer to bacillus Calmette-Guérin and gemcitabine-docetaxel therapy.","authors":"Ahmed Eraky, Kaushik P Kolanukuduru, Brenda Hug, Reuben Ben-David, Kyrollis Attalla, Nikhil Waingankar, Peter Wiklund, Reza Mehrazin, John P Sfakianos","doi":"10.1016/j.urolonc.2025.03.009","DOIUrl":"https://doi.org/10.1016/j.urolonc.2025.03.009","url":null,"abstract":"<p><strong>Background and objective: </strong>Sequential intravesical gemcitabine/docetaxel (Gem/Doce) is a potential alternative to bacillus Calmette-Guérin (BCG) for treating non-muscle-invasive bladder cancer (NMIBC). Intermediate-risk NMIBC group (IR-NMIBC) includes both low-grade (LG) and high-grade tumors (HG). This study investigates the response of HG and LG IR-NMIBC to Gem/Doce compared to BCG therapy.</p><p><strong>Methods: </strong>We included patients with IR-NMIBC who received either BCG or Gem/Doce between 2013 and 2023. Maintenance regimens were administered to patients without recurrence after induction for 1 year. Follow-up cystoscopies were performed per American Urological Association (AUA) guidelines. Kaplan-Meier and Cox regression analyses were performed to evaluate recurrence-free survival (RFS) and progression-free survival (PFS).</p><p><strong>Results: </strong>Among 505 NMIBC patients, 150 were IR-NMIBC: 115 with HG tumors (69 received BCG, 46 received Gem/Doce) and 35 with LG tumors (14 received BCG, 21 received Gem/Doce).With a median follow-up time of 31 months (Interquartile Range [IQR] 13-54), The overall 2-year any-grade RFS was 55%. For HG and LG groups, the 2-year any-grade RFS was 58% and 35% (P = 0.009), respectively. High-grade RFS at 2 years was 75% for HG and 94% for LG (P = 0.065). The 2-year PFS was similar between groups, at 96% for both HG and LG (P = 0.39). In HG patients, 2-year high-grade RFS was higher with BCG than Gem/Doce (81% vs. 59%, P = 0.008). In LG patients, 2-year any-grade and high-grade RFS were comparable between BCG and Gem/Doce (P = 0.067 and P = 0.37, respectively).</p><p><strong>Conclusions: </strong>Our findings suggest that BCG may offer a superior benefit in terms of high-grade RFS for HG IR-NMIBC compared to Gem/Doce, while LG tumors respond similarly to both treatments. This emphasizes the role of risk stratification in treatment selection. Prospective studies are needed to validate these findings and refine treatment strategies.</p>","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143765219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Clinician interest in clinical decision support for PSA-based prostate cancer screening\" [Urol Oncol: Semin Original Investigat. 41(3) March 2023, 145.e17-145.e23].","authors":"Jonathan Harper, Trevor C Hunt, Mouneeb Choudry, Ashley L Kapron, Kathleen A Cooney, Christopher Martin, Jacob Ambrose, Brock O'Neil","doi":"10.1016/j.urolonc.2025.03.010","DOIUrl":"https://doi.org/10.1016/j.urolonc.2025.03.010","url":null,"abstract":"","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143744088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to 'Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide'[Urol Oncol: Semin Original Investigat 41(3) (2023) 253.e1-253.e9].","authors":"Benjamin Lowentritt, Dominic Pilon, Ibrahim Khilfeh, Carmine Rossi, Erik Muser, Frederic Kinkead, Dexter Waters, Lorie Ellis, Patrick Lefebvre, Gordon Brown","doi":"10.1016/j.urolonc.2025.03.011","DOIUrl":"https://doi.org/10.1016/j.urolonc.2025.03.011","url":null,"abstract":"","PeriodicalId":23408,"journal":{"name":"Urologic Oncology-seminars and Original Investigations","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143744090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}